Premature Ejaculation Epidemiology Forecast 2025-2034

According to the National Health and Social Life Survey (NHSLS), the prevalence of premature ejaculation is around 30%, which is consistent across all adult age categories. It is also indicated that 30% to 70% of American men are affected by premature ejaculation.

Premature Ejaculation Epidemiology Forecast Report Coverage

The “Premature Ejaculation Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of premature ejaculation. It projects the future incidence and prevalence rates of premature ejaculation across various populations. The study covers age and type as major determinants of the premature ejaculation-affected population. The report highlights patterns in the prevalence of premature ejaculation over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of premature ejaculation in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Premature Ejaculation: Disease Overview

Premature ejaculation is a prevalent male sexual dysfunction, characterized by ejaculation that occurs sooner than desired. It can cause relationship difficulties, personal distress, and a reduced quality of life. Premature ejaculation can be classified into two types: lifelong (primary) premature ejaculation and acquired (secondary) premature ejaculation. A combination of physiological, psychological (anxiety, stress, depression, etc.), and genetic factors are indicated to cause this sexual dysfunction in males.

Premature Ejaculation: Treatment Overview

For the treatment of premature ejaculation, pharmacological therapies, behavioral techniques, and psychological support are suggested. Oral medications such as selective serotonin reuptake inhibitors (SSRIs) including paroxetine, sertraline, and fluoxetine, are widely used off-label for premature ejaculation. They help in delaying ejaculation by increasing serotonin levels in the central nervous system. A short-acting SSRI called dapoxetine is specifically approved for premature ejaculation in some countries and exhibits fewer side effects compared to traditional SSRIs. Topical anesthetics like lidocaine-prilocaine creams or sprays are also recommended for reducing penile sensitivity to delay ejaculation.

Epidemiology

The premature ejaculation epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for premature ejaculation by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for premature ejaculation and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• As per the National Health and Social Life Survey (NHSLS), the prevalence of premature ejaculation is estimated to be 30% and is observed to be consistent across all adult age categories, unlike erectile dysfunction.
• Premature ejaculation is considered the most common type of sexual dysfunction that occurs in individuals having a penis, with approximately 1 in 5 people aged between 18 to 59 years experiencing the condition.
• Premature ejaculation is reported to occur at any age in an adult man’s life but is found most prevalent in men between the ages of 18 and 30. It is also recorded to occur in conjunction with secondary impotence in males between the ages of 45 and 65 years.
• Around 1 in 3 men in the United States falling between the ages of 18 and 59 have reported problems with premature ejaculation, including both primary and acquired types.

Country-wise Premature Ejaculation Epidemiology

The premature ejaculation epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of premature ejaculation varies significantly between countries due to differences in genetic predispositions, healthcare infrastructure, cultural perceptions of sexual health, and diagnostic criteria, among others. Genetic and biological factors, such as variations in serotonin receptor sensitivity, are likely to influence the prevalence rates in a region. In the United States, it is estimated that 30% to 70% of the male population experience premature ejaculation.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of premature ejaculation based on several factors.
• Premature Ejaculation Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of premature ejaculation are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of premature ejaculation epidemiology in the 8 major markets?
• What will be the total number of patients with premature ejaculation across the 8 major markets during the forecast period?
• What was the country-wise prevalence of premature ejaculation in the 8 major markets in the historical period?
• Which country will have the highest number of premature ejaculation patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of premature ejaculation during the forecast period of 2025-2034?
• What are the currently available treatments for premature ejaculation?
• What are the disease risks, signs, symptoms, and unmet needs of premature ejaculation?

This product will be delivered within 3-5 business days.